

Resource Summary Report

Generated by PRECISE-TBI on Jul 30, 2026

PE anti-human EGFR

RRID:AB_10896794

Type: Antibody

Proper Citation

BioLegend Cat# 352904, RRID:AB_10896794

Antibody Information

URL: http://antibodyregistry.org/AB_10896794

Proper Citation: BioLegend Cat# 352904, RRID:AB_10896794

Target Antigen: EGFR

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE anti-human EGFR

Description: This monoclonal targets EGFR

Target Organism: human

Clone ID: Clone AY13

Antibody ID: AB_10896794

Vendor: BioLegend

Catalog Number: 352904

Alternative Catalog Numbers: 352903

Record Creation Time: 20250819T233224+0000

Record Last Update: 20250820T053857+0000

Ratings and Alerts

No rating or validation information has been found for PE anti-human EGFR.

No alerts have been found for PE anti-human EGFR.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. Cell stem cell, 32(7), 1087.

Denk D, et al. (2025) IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. Immunity, 58(3), 701.

Barra JM, et al. (2024) Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells. Cell reports, 43(11), 114994.

Shah Z, et al. (2024) Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell stem cell, 31(6), 803.

Tian M, et al. (2023) Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. Cell reports. Medicine, 4(10), 101212.

Bosse KR, et al. (2022) Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. Cancer discovery, 12(12), 2800.